Colchicine
- Generic Name
- Colchicine
- Brand Names
- Colcrys, Gloperba, Lodoco, Mitigare
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25NO6
- CAS Number
- 64-86-8
- Unique Ingredient Identifier
- SML2Y3J35T
- Background
Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.
- Indication
Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.
- Associated Conditions
- Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke
The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Tor Biering-Sørensen
- Target Recruit Count
- 152
- Registration Number
- NCT06081049
- Locations
- 🇩🇰
Center for Translational Cardiology and Pragmatic Randomized Trials, Herlev and Gentofte Hospital, Hellerup, Denmark
COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE)
- Conditions
- AtherosclerosisIschemic Stroke
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- University College Dublin
- Target Recruit Count
- 91
- Registration Number
- NCT06062277
- Locations
- 🇮🇪
Stroke Clinical Trials Network Ireland, Dublin, Ireland
The Effect of Colchicine on Inflammation in ACS Patients
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 88
- Registration Number
- NCT06054100
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
- Conditions
- Elderly PatientsPercutaneous Coronary InterventionC-Reactive ProteinMultivessel Coronary Artery Disease
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT06025071
- Locations
- 🇨🇳
Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS & PUMC, Beijing, Beijing, China
Short Course Low Dose Oral Colchicine After ST Elevation Myocardial Infarction(STEMI)
- Conditions
- STEMI
- Interventions
- Drug: Oral Pyridoxine 10 mg
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- National University of Malaysia
- Target Recruit Count
- 64
- Registration Number
- NCT06020300
- Locations
- 🇲🇾
Nationa University of Malaysia, Kuala Lumpur, Wilayah Persekutuan, Malaysia
Effect of Low Dose of Colchicine on Platelet Reactivity
- Conditions
- Coronary Artery DiseasePlatelet Aggregation, Spontaneous
- Interventions
- Other: Placebo
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 80
- Registration Number
- NCT05956145
- Locations
- 🇧🇷
Heart Institute (InCor) / University of São Paulo, São Paulo, Sao Paulo, Brazil
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
- Conditions
- Type 1 DiabetesCardiovascular DiseasesChronic Inflammation
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Asger Lund, MD
- Target Recruit Count
- 100
- Registration Number
- NCT05949281
- Locations
- 🇩🇰
Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Capital Region, Denmark
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
- Conditions
- GoutGout Initiating Urate-loweringUrate-lowering Therapy
- Interventions
- Drug: Genakumab for injection
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT05936281
- Locations
- 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
- Conditions
- Acute GoutGout Flare
- Interventions
- Drug: Genakumab for injection
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT05936268
- Locations
- 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China
Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 120
- Registration Number
- NCT05930002
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.